Epigenetics Market worth $3.92 billion in 2031
The report "Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031" is expected to reach USD 3.92 billion by 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period.
Browse 630 market data Tables and 61 Figures spread through 487 Pages and in-depth TOC on "Epigenetics Market By Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html
The epigenetics market is experiencing significant growth, driven by the rising use of epigenomic profiling in oncology, precision medicine, drug discovery, and biomarker research. Pharmaceutical and biotechnology companies are increasingly adopting technologies such as DNA methylation analysis, ChIP-seq, ATAC-seq, RNA sequencing, and NGS-based epigenetic profiling to study gene regulation, disease progression, therapeutic response, and target identification. The growing focus on liquid biopsy-based epigenetic biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is further supporting market expansion, particularly across cancer diagnostics, translational research, and personalized therapy development. However, the market continues to face challenges such as high sequencing and data analysis costs, complexity of epigenetic data interpretation, variability in antibody quality for histone modification studies, and difficulties in standardizing workflows across research and clinical applications.
By product, the kits & reagents segment held the largest share of the epigenetics market in 2025.
By product, the epigenetics market is segmented into kits & reagents, enzymes, and instruments & accessories. In 2025, kits & reagents accounted for the largest market share. This is primarily due to their recurring use across DNA methylation analysis, histone modification studies, chromatin accessibility assays, ChIP-seq, bisulfite sequencing, ATAC-seq, PCR-based epigenetic assays, and NGS-based epigenomic profiling. Kits & reagents are widely used by pharmaceutical and biotechnology companies, academic research institutes, clinical laboratories, and CROs for sample preparation, library preparation, target enrichment, biomarker discovery, and validation studies. Their high consumption frequency, protocol-specific requirements, and critical role in ensuring assay reproducibility support their dominance in the market. The increasing adoption of precision medicine, cancer epigenetics research, liquid biopsy-based methylation testing, and multi-omics workflows further strengthens demand for kits & reagents in the epigenetics market.
By technology, the next-generation sequencing segment held the largest share of the epigenetics market in 2025.
By technology, the epigenetics market is segmented into next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies. In 2025, next-generation sequencing accounted for the largest market share. This is primarily due to its extensive use in DNA methylation profiling, ChIP-seq, ATAC-seq, RNA-based epigenetic analysis, chromatin accessibility studies, and genome-wide epigenomic mapping. NGS enables high-throughput, sensitive, and comprehensive analysis of epigenetic modifications, making it widely adopted across oncology research, biomarker discovery, drug development, precision medicine, and translational studies. Pharmaceutical and biotechnology companies, academic institutes, clinical laboratories, and CROs increasingly rely on NGS-based workflows for large-scale epigenetic profiling and multi-omics integration. The growing demand for liquid biopsy-based methylation biomarkers, single-cell epigenomics, and advanced cancer diagnostics further supports the leading position of the NGS segment in the epigenetics market.
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America held the largest share of the epigenetics market. This is supported by strong biomedical research infrastructure, high adoption of NGS-based epigenomic profiling, significant investment in oncology, precision medicine, and drug discovery research, and the presence of leading pharmaceutical and biotechnology companies, academic institutes, clinical laboratories, and CROs. The growing use of epigenetic technologies in cancer diagnostics, therapeutic target identification, biomarker validation, and multi-omics research continues to drive demand across the region. Ongoing advancements in sequencing platforms, bioinformatics tools, and AI-enabled data interpretation are further supporting market growth in North America.
Some of the leading players in the market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Promega Corporation (US), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Epigenetics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
